Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

(2015) Ryan B. Corcoran et al.   Oncotarget

Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations

(2015) Ludovica Ciuffreda et al.   NEOPLASIA

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

(2015) Anwar R. Padhani et al.   NEOPLASIA

Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology

(2015) Mary E. Loveless et al.   NEOPLASIA

Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and18F-FLT PET imaging

(2013) Oussama Karroum et al.   Contrast Media & Molecular Imaging

Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

(2012) N Tunariu et al.   BRITISH JOURNAL OF CANCER

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function

(2012) L C J Baker et al.   BRITISH JOURNAL OF CANCER

Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development

(2012) Ralph Sinkus et al.   EUROPEAN JOURNAL OF CANCER

Qualification of imaging biomarkers for oncology drug development

(2012) John C. Waterton et al.   EUROPEAN JOURNAL OF CANCER

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCNTransgenic Mouse Model of Neuroblastoma

(2012) Yann Jamin et al.   RADIOLOGY

Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR

(2011) Paul Workman et al.   CANCER CELL

Histone Deacetylase Inhibition Increases Levels of Choline Kinase   and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers

(2011) M. Beloueche-Babari et al.   CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

(2010) Jaafar Bennouna et al.   INVESTIGATIONAL NEW DRUGS

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients

(2010) Lei Tang et al.   RADIOLOGY

Diffusion-Weighted MRI of Advanced Hepatocellular Carcinoma During Sorafenib Treatment: Initial Results

(2009) Christina Schraml et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

(2009) R E Board et al.   BRITISH JOURNAL OF CANCER

Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability

(2009) P. M.J. McSheehy et al.   CLINICAL CANCER RESEARCH

From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs

(2009) CP Carden et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial

(2009) Dow-Mu Koh et al.   EUROPEAN RADIOLOGY

MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model

(2009) S.O. Aliu et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors

(2009) Simon Walker-Samuel et al.   MAGNETIC RESONANCE IN MEDICINE

Early Therapy Evaluation of Combined Anti-Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging

(2008) H. Kim et al.   CANCER RESEARCH

Biomarkers In Early Clinical Trials: the Committed and the Skeptics

(2008) U. Banerji et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY